*仅供医学专业人士阅读参考把肿瘤微环境内因抗原慢性刺激转入耗竭状态的CD8+T细胞“叫醒”，让它们重新活化为效应CD8+T细胞，是PD-1/L1抑制剂为代表的现有免疫治疗起效的关键，但实话实说，激活处在耗竭状态的CD8+T细胞，在奇点糕眼里总觉得有点 ...

This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...

NADIM 研究是第一项评估化疗联合免疫检查点抑制剂围术期治疗潜在可切除 IIIA 期非小细胞肺癌（NSCLC）的研究，前期研究结果显示[1]，意向性治疗（ITT）人群的 2 年无进展生存（PFS）率达 ...

*仅供医学专业人士阅读参考在目前已经获批的各种免疫联合治疗方案里，PD-1/L1抑制剂和CTLA-4抑制剂组成的“双免疫方案”，经常给奇点糕一种双刃剑的感觉，一方面它们确实取得了不少关键临床研究的成功，对非小细胞肺癌（NSCLC）、肝癌等常见实体瘤有 ...

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...

The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

2024年欧洲肿瘤内科学会（ESMO）大会于9月13日至17日在西班牙巴塞罗那举行。期间，北京大学肿瘤医院彭智教授以口头报告的形式公布了“SHR-1701联合化疗对比安慰剂联合化疗用于HER2阴性胃或胃食管结合部腺癌 ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...